112 related articles for article (PubMed ID: 1547879)
1. Long-term survival in acute lymphoblastic leukaemia in adults: a prospective study of 51 patients. Finnish Leukaemia Group.
Eur J Haematol; 1992 Feb; 48(2):75-82. PubMed ID: 1547879
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of adult acute lymphoblastic leukemia with Ad-VP-L regimen].
Umeda M; Shikoshi K; Anno S; Su CY; Shirai T
Rinsho Ketsueki; 1991 Jan; 32(1):6-10. PubMed ID: 2020119
[TBL] [Abstract][Full Text] [Related]
4. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group].
Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T
Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
6. Late intensification chemotherapy has not improved the results of intensive chemotherapy in adult acute lymphoblastic leukemia. Results of a prospective multicenter randomized trial (PETHEMA ALL-89). Spanish Society of Hematology.
Ribera JM; Ortega JJ; Oriol A; Fontanillas M; Hernández-Rivas JM; Brunet S; García-Conde J; Maldonado J; Zuazu J; Gardella S; Besalduch J; León P; Macià J; Domingo-Albós A; Feliu E; San Miguel JF
Haematologica; 1998 Mar; 83(3):222-30. PubMed ID: 9573676
[TBL] [Abstract][Full Text] [Related]
7. [Treatment of 71 adult acute lymphoblastic leukemia].
Yoshida M; Kurata H; Tsunoda S; Iwama A; Suzuki T; Akutsu M; Imagawa S; Tsunoda J; Furukawa Y; Komatsu N
Gan To Kagaku Ryoho; 1993 Sep; 20(12):1827-33. PubMed ID: 8379676
[TBL] [Abstract][Full Text] [Related]
8. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E;
Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744
[TBL] [Abstract][Full Text] [Related]
9. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen.
Storring JM; Minden MD; Kao S; Gupta V; Schuh AC; Schimmer AD; Yee KW; Kamel-Reid S; Chang H; Lipton JH; Messner HA; Xu W; Brandwein JM
Br J Haematol; 2009 Jun; 146(1):76-85. PubMed ID: 19438471
[TBL] [Abstract][Full Text] [Related]
10. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
[TBL] [Abstract][Full Text] [Related]
11. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen.
Weiser MA; Cabanillas ME; Konopleva M; Thomas DA; Pierce SA; Escalante CP; Kantarjian HM; O'Brien SM
Cancer; 2004 Mar; 100(6):1179-85. PubMed ID: 15022284
[TBL] [Abstract][Full Text] [Related]
12. Treatment of high-risk acute lymphoblastic leukemia in children using the AL851 and ALHR88 protocols: a report from the Kyushu-Yamaguchi Children's Cancer Study Group in Japan.
Matsuzaki A; Ishii E; Okamura J; Eguchi H; Yoshida N; Yanai F; Inoue T; Miyake K; Ishihara T; Tsuboi C
Med Pediatr Oncol; 1996 Jan; 26(1):10-9. PubMed ID: 7494507
[TBL] [Abstract][Full Text] [Related]
13. [The results of using differentiated programs of therapy in acute lymphoblastic leukemia in adults].
Volkova MA; Perilov AA; Kaletin GI; Tupitsyn NN; Frenkel' MA; Fleĭshman EV
Ter Arkh; 1991; 63(7):109-11. PubMed ID: 1788786
[TBL] [Abstract][Full Text] [Related]
14. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors.
Revesz D; Chelghoum Y; Le QH; Elhamri M; Michallet M; Thomas X
Ann Hematol; 2003 Nov; 82(11):684-90. PubMed ID: 12928754
[TBL] [Abstract][Full Text] [Related]
15. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study.
Takeuchi J; Kyo T; Naito K; Sao H; Takahashi M; Miyawaki S; Kuriyama K; Ohtake S; Yagasaki F; Murakami H; Asou N; Ino T; Okamoto T; Usui N; Nishimura M; Shinagawa K; Fukushima T; Taguchi H; Morii T; Mizuta S; Akiyama H; Nakamura Y; Ohshima T; Ohno R
Leukemia; 2002 Jul; 16(7):1259-66. PubMed ID: 12094249
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors and outcome of therapy in adult acute lymphoblastic leukemia.
Philips GK; Crowell EB; Mani A
Indian J Cancer; 1991 Sep; 28(3):148-54. PubMed ID: 1786981
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acute lymphoblastic leukaemia in adults with modified BFM regimen.
Kudva GC; Chandy M; Dennison D; Srivastava A; Bhushan V
Indian J Cancer; 1994 Mar; 31(1):1-7. PubMed ID: 8063329
[TBL] [Abstract][Full Text] [Related]
18. Results of risk-adapted therapy in acute myeloid leukaemia. A long-term population-based follow-up study.
Wahlin A; Billström R; Björ O; Ahlgren T; Hedenus M; Höglund M; Lindmark A; Markevärn B; Nilsson B; Sallerfors B; Brune M
Eur J Haematol; 2009 Aug; 83(2):99-107. PubMed ID: 19385987
[TBL] [Abstract][Full Text] [Related]
19. Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen.
Weiser MA; O'Brien S; Thomas DA; Pierce SA; Lam TP; Kantarjian HM
Cancer; 2002 Jan; 94(2):285-91. PubMed ID: 11900213
[TBL] [Abstract][Full Text] [Related]
20. Treatment of adult acute lymphoblastic leukaemia (ALL) over a 16 year period.
Bassan R; Battista R; Rohatiner AZ; Love S; Carter M; Buelli M; Viero P; D'Emilio A; MacCallum P; Amess J
Leukemia; 1992; 6 Suppl 2():186-90. PubMed ID: 1578929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
